Broadly Reactive IgG Responses to Heterologous H5 Prime-Boost Influenza Vaccination Are Shaped by Antigenic Relatedness to Priming Strains

Wang, Jiong; Li, Dongmei; Perry, S. Scott; Hilchey, Shannon P.; Wiltse, Alexander; Treanor, John J.; Sangster, Mark Y.; Zand, Martin S.

doi:10.1128/mbio.00449-21

Cited by 12 publications

(14 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We estimated the concentrations of HCoV S or N IgG antibodies in each sample with the standard curve of each analyte generated with eight 1:4 serial dilutions of STD-CoV serum as previously described (17,20,21). Duplicates of 50mL diluted STD-CoV were mixed with 50mL of the HCoV bead panel mixture containing 1,000 coupled beads per analyte.…”

Section: Five Parameter Logistic Curve Estimation Of Antibody Concentrationmentioning

confidence: 99%

“…Using the anti-HCoVs positive control standard serum (STD-CoV) in mPlex-CoV assay, we next generated 5 parameter logistic curves to map the assay MFI results to antigen-specific antibody concentrations with the method previously described for influenza anti-hemagglutinin antibodies (19)(20)(21). This allows direct comparison of absolute individual isotype antibody concentrations against each target strain HCoV S or N protein.…”

Section: Quantifying Human Anti-hcov S and N Igg Iga And Igmmentioning

confidence: 99%

“…Multiplex systems serology assays that measure IgG binding for multiple antigens have been used to quantify antigenic distances between viral strains, track antibody cross-reactivity due to prior IgG exposure to similar viral strains, and provide quantitative measurements of IgG repertoire changes after infection or vaccination (17). We have previously described an influenza anti-hemagglutinin multiplex assay, mPlex-Flu, that has a continuous linear readout over 4.5 logs, and low Type-I (false positives, specificity) and Type-II (false negatives, sensitivity) errors (18)(19)(20). The mPlex-Flu assay provides absolute concentrations of antibodies against up to 50 target analytes (17,(21)(22)(23) with extremely low inter-and intra-assay variance, greater precision of clinical trial group statistical comparisons (20,24), and a very high correlation with functional viral binding and inhibition assays.…”

Section: Introductionmentioning

confidence: 99%

“…We have previously described an influenza anti-hemagglutinin multiplex assay, mPlex-Flu, that has a continuous linear readout over 4.5 logs, and low Type-I (false positives, specificity) and Type-II (false negatives, sensitivity) errors (18)(19)(20). The mPlex-Flu assay provides absolute concentrations of antibodies against up to 50 target analytes (17,(21)(22)(23) with extremely low inter-and intra-assay variance, greater precision of clinical trial group statistical comparisons (20,24), and a very high correlation with functional viral binding and inhibition assays. It allows for rapid characterization of the similarity between the dominant antigens of disparate influenza viral strains.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Antibody Mediated Immunity to SARS-CoV-2 and Human Coronaviruses: Multiplex Beads Assay and Volumetric Absorptive Microsampling to Generate Immune Repertoire Cartography

Wang

Zhou

et al. 2021

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

The COVID-19 pandemic is caused by SARS-CoV-2, a novel zoonotic coronavirus. Emerging evidence indicates that preexisting humoral immunity against other seasonal human coronaviruses (HCoVs) plays a critical role in the specific antibody response to SARS-CoV-2. However, current work to assess the effects of preexisting and cross-reactive anti-HCoVs antibodies has been limited. To address this issue, we have adapted our previously reported multiplex assay to simultaneously and quantitatively measure anti-HCoV antibodies. The full mPlex-CoV panel covers the spike (S) and nucleocapsid (N) proteins of three highly pathogenic HCoVs (SARS-CoV-1, SARS-CoV-2, MERS) and four human seasonal strains (OC43, HKU1, NL63, 229E). Combining this assay with volumetric absorptive microsampling (VAMS), we measured the anti-HCoV IgG, IgA, and IgM antibodies in fingerstick blood samples. The results demonstrate that the mPlex-CoV assay has high specificity and sensitivity. It can detect strain-specific anti-HCoV antibodies down to 0.1 ng/ml with 4 log assay range and with low intra- and inter-assay coefficients of variation (%CV). We also estimate multiple strain HCoVs IgG, IgA and IgM concentration in VAMS samples in three categories of subjects: pre-COVID-19 (n=21), post-COVID-19 convalescents (n=19), and COVID-19 vaccine recipients (n=14). Using metric multidimensional scaling (MDS) analysis, HCoVs IgG concentrations in fingerstick blood samples were well separated between the pre-COVID-19, post-COVID-19 convalescents, and COVID-19 vaccine recipients. In addition, we demonstrate how multi-dimensional scaling analysis can be used to visualize IgG mediated antibody immunity against multiple human coronaviruses. We conclude that the combination of VAMS and the mPlex-Cov assay is well suited to performing remote study sample collection under pandemic conditions to monitor HCoVs antibody responses in population studies.

show abstract

Section: Five Parameter Logistic Curve Estimation Of Antibody Concentrationmentioning

confidence: 99%

Section: Quantifying Human Anti-hcov S and N Igg Iga And Igmmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Antibody Mediated Immunity to SARS-CoV-2 and Human Coronaviruses: Multiplex Beads Assay and Volumetric Absorptive Microsampling to Generate Immune Repertoire Cartography

Wang

Zhou

et al. 2021

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Antibody cross-reactivity across different viral strains is an important source of pre-existing immunity to emerging viral variants (26, 27, 10). Similarly, vaccination against a new viral strain may “back-boost” cross-reactive immunity to previously circulating strains (28, 29). This appears to be the case for SARS-CoV-2.…”

Section: Introductionmentioning

confidence: 99%

Broad Cross-reactive IgA and IgG Against Human Coronaviruses in Milk Induced by COVID-19 Vaccination and Infection

Wang

Young

Li³

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

It is currently unclear if SARS-CoV-2 infection or mRNA vaccination can also induce IgG and IgA against common human coronaviruses (HCoVs) in lactating parents. Here we prospectively analyzed human milk (HM) and blood samples from lactating parents to measure the temporal patterns of anti-SARS-CoV-2 specific and anti-HCoV cross-reactive IgA and IgG responses. Two cohorts were analyzed: a vaccination cohort (n=30) who received mRNA-based vaccines for COVID-19 (mRNA-1273 or BNT162b2), and an infection cohort (n=45) with COVID-19 disease. Longitudinal HM and fingerstick blood samples were collected pre- and post-vaccination or, for infected subjects, at 5 time-points 14 - 28 days after confirmed diagnosis. The anti-spike(S) and anti-nucleocapsid(N) IgA and IgG antibody levels against SARS-CoV-2 and HCoVs were measured by multiplex immunoassay (mPlex-CoV). We found that vaccination significantly increased the anti-S IgA and IgG levels in HM. In contrast, while IgG levels increased after a second vaccine dose, blood and HM IgA started to decrease. Moreover, HM and blood anti-S IgG levels were significantly correlated, but anti-S IgA levels were not. SARS2 acute infection elicited anti-S IgG and IgA that showed much higher correlations between HM and blood compared to vaccination. Vaccination and infection were able to significantly increase the broadly cross-reactive IgG recognizing HCoVs in HM and blood than the IgA antibodies in HM and blood. In addition, the broader cross-reactivity of IgG in HM versus blood indicates that COVID-19 vaccination and infection might provide passive immunity through HM for the breastfed infants not only against SARS-CoV-2 but also against common cold coronaviruses.

show abstract

Vaccine efficacy induced by 2020-2021 seasonal influenza-derived H3N1 virus-like particles co-expressing M2e5x or N2

Mao,

Kang,

Eom

et al. 2025

Vaccine

View full text Add to dashboard Cite

Broadly Reactive IgG Responses to Heterologous H5 Prime-Boost Influenza Vaccination Are Shaped by Antigenic Relatedness to Priming Strains

Cited by 12 publications

References 48 publications

Antibody Mediated Immunity to SARS-CoV-2 and Human Coronaviruses: Multiplex Beads Assay and Volumetric Absorptive Microsampling to Generate Immune Repertoire Cartography

Antibody Mediated Immunity to SARS-CoV-2 and Human Coronaviruses: Multiplex Beads Assay and Volumetric Absorptive Microsampling to Generate Immune Repertoire Cartography

Broad Cross-reactive IgA and IgG Against Human Coronaviruses in Milk Induced by COVID-19 Vaccination and Infection

Vaccine efficacy induced by 2020-2021 seasonal influenza-derived H3N1 virus-like particles co-expressing M2e5x or N2

Contact Info

Product

Resources

About